loading page

Pharmacokinetics-pharmacodynamics of first line antitubercular drugs: A comparative study in tuberculosis patients with and without concomitant diabetes mellitus
  • +3
  • Sourav Mondal,
  • Vandana Roy,
  • Girish Meshram,
  • Ashwani Khanna,
  • Thirumurthy Velpandian,
  • Sandeep Garg
Sourav Mondal
Maulana Azad Medical College
Author Profile
Vandana Roy
Maulana Azad Medical College

Corresponding Author:roy.vandana@gmail.com

Author Profile
Girish Meshram
Maulana Azad Medical College
Author Profile
Ashwani Khanna
Maulana Azad Medical College
Author Profile
Thirumurthy Velpandian
All India Institute of Medical Sciences
Author Profile
Sandeep Garg
Maulana Azad Medical College
Author Profile

Abstract

Aim To observe the plasma concentrations and pharmacokinetic-pharmacodynamic (PK-PD) profile of first-line antitubercular drugs in pulmonary tuberculosis (TB) patients with and without diabetes mellitus (DM). Methods Newly diagnosed pulmonary TB patients aged 18-60 with or without DM were included in the study. Group I (n = 20) included patients with TB, whereas Group II (n = 20) contained patients with TB and DM. After 2 weeks of therapy, plasma concentrations and other PK-PD parameters were determined. The improvement in clinical features, X-ray findings, sputum conversion and adverse drug reactions (ADRs) were measured after 2 months of ATT. Results Isoniazid displayed non-significantly higher plasma concentrations in diabetic patients, along with a significantly (P < 0.05) longer elimination half-life (t1/2). Rifampicin plasma concentration at 4, 8, and 12 h were significantly (P < 0.05) lower and it displayed significantly (P < 0.05) lower area under curves (AUC0-12 and AUC0-), shorter t1/2, higher clearance (Cl) and a lower AUC0-/MIC ratio in diabetic patients. Pyrazinamide and ethambutol showed non-significantly higher plasma concentrations, AUC0-12, AUC0-, and t1/2 in diabetic patients. The improvement in clinical features, X-ray findings, sputum conversion, and ADRs were comparable in both the groups. Conclusions The presence of DM in TB patients affects the PK-PD parameters of isoniazid, rifampicin, pyrazinamide and ethambutol variably in the Indian population. Studies in a larger number of patients are required to further elucidate the role of DM on the PK-PD profile of first-line antitubercular drugs and treatment outcomes in TB patients with concomitant DM.